AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 71 min read$ALAB

ALBA MANUEL sold $60.5M of ALAB (indirect holdings)

ALBA MANUEL sold 136,974 indirectly-held shares of Astera Labs, Inc. (ALAB) at an average of $442.01 ($429.58–$459.02, $60.54M total) across 29 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ALBA MANUEL
Published Jul 7, 2026, 1:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling size and timing, but it does not include new company fundamentals (no guidance, earnings, or deal terms).

02

Market read

Traders may monitor for follow-on insider activity or correlate with price/volume, but the 10b5-1 framing suggests limited incremental information.

03

What to watch

The filing notes indirect holdings and multiple trades across a price range; without context on total compensation or prior sale cadence, the market may overinterpret the signal.

Relevance 7/10Novelty 5/10Timing: Form 4 filed July 6 for July 1 insider sale.

Background

This is an SEC Form 4 insider transaction for Astera Labs, Inc. (ALAB) by director Alba Manuel, executed as an open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs director Alba Manuel sold $60.54M of ALAB shares via an open-market sale under a pre-arranged 10b5-1 plan on July 1.

Expected impact

Near-term impact likely limited; any reaction should fade unless accompanied by other news.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces the signal of new negative information.

Market effects

Sector

No sector read-through is provided beyond a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity/portfolio rebalancing rather than bearish expectations.

Key entities

  • issuer
    Astera Labs, Inc.

    Company whose shares were sold by a director under a 10b5-1 plan.

  • insider
    Alba Manuel

    Director reporting an open-market sale of ALAB shares via indirect holdings.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALAB insider trading history →

Related articles

OCT 9
$ALABMed

Astera Labs Stock Fell 9% in a Day as an OpenAI Revenue Report Hit Chip Stocks. Here’s Where the Stock Could Go by 2030

Astera Labs (ALAB) stock dropped 9.21% to $347.05 on October 8, following a broader chip sector sell-off triggered by OpenAI's lower-than-expected revenue report. The company launched Aries 7, its PCIe 7 signal conditioning portfolio. Despite a 23% rise in 2026 revenue forecasts to $1.91B, free cash flow fell 49.6% YoY to $67.21M, raising concerns. Analysts' target prices range from $390 to $850, with a potential total return of 146%.

finance.yahoo.com2 min
OCT 7
$ALABMed

Why is Astera Labs stock sliding today?

Astera Labs (ALAB) stock dropped 5.0% after Zacks Research downgraded it from 'strong buy' to 'hold', following a 10% surge on S&P 500 inclusion speculation. Insider selling and high valuation also pressured the stock, with broader market declines adding to the downturn. Competitors like Marvell Technology intensify the competitive landscape. The stock remains sensitive to macroeconomic factors and analyst commentary.

investing.com2 min
OCT 6
$ALABHigh

Why is Astera Labs stock surging today?

Astera Labs (ALAB) stock surged 9.5% to $396.82, with traders anticipating its inclusion in the S&P 500. The company reported Q2 revenue of $392.4M, beating estimates, and guided Q3 revenue to $540M–$560M. Analysts, including Fubon, have upgraded the stock, with a $500 price target. The S&P 500 and Nasdaq each rose 0.7% today.

investing.com2 min
SEP 16
$ALABMed

ALAB Stock Holds Support As High Valuation Tests Traders

Astera Labs Inc. (ALAB) stock rose 6.54% due to strong AI infrastructure demand. The company reported $392.4M in quarterly revenue, $153.1M in net income, and $67.2M in free cash flow. ALAB trades at 127x earnings and 37x sales, with a strong balance sheet but high valuation concerns. Traders are watching key price levels around $262–$265 and $272–$275.

stockstotrade.com2 min
SEP 16
$ALABMed

ALAB Broadens Leo Portfolio: Can It Stay Ahead of MRVL & CRDO?

Astera Labs (ALAB) reported record Q2 2026 revenue growth, driven by AI connectivity products. The company expanded its Leo CXL memory controller portfolio, gaining hyperscaler traction. Q3 2026 revenue is expected between $540M and $560M. Competitors Marvell (MRVL) and Credo (CRDO) are also advancing in AI connectivity. ALAB shares rose 51.8% YTD, with a forward P/S of 16.16X.

theglobeandmail.com2 min